Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.39 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.37 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13708582 | 0.87 | PARP1 (0.42) | PARP1HDAC1MAPK14CAMK2DMAPK13 | |
| SCHEMBL4084666 | 0.87 | PARP1 (0.42) | PARP1HDAC1MAPK14CAMK2DMAPK13 | |
| SCHEMBL4084220 | 0.87 | PARP1 (0.42) | PARP1HDAC1MAPK14CAMK2DMAPK13 | |
| SCHEMBL4089996 | 0.87 | HDAC1 (0.40) | PARP1HDAC1MAPK14CAMK2DPFKFB3 | |
| SCHEMBL4096958 | 0.85 | PARP1 (0.40) | PARP1HDAC1MAPK14CAMK2DPFKFB3 | |
| SCHEMBL5981354 | 0.85 | PARP1 (0.41) | PARP1HDAC1MAPK8GPR119ACACB | |
| SCHEMBL4089979 | 0.84 | HDAC1 (0.46) | PARP1HDAC1MAPK14CAMK2DMAPK8 | |
| SCHEMBL4091170 | 0.84 | PARP1 (0.46) | PARP1HDAC1MAPK8GPR119ACACB | |
| SCHEMBL13708590 | 0.84 | MAPK14 (0.46) | MAPK14CAMK2DMAPK13MAPK12MAPK11 | |
| SCHEMBL4094473 | 0.84 | MAPK14 (0.46) | MAPK14CAMK2DMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582631-B2 | Paget's disease; muscular disorders; cardiovascular disorders; antiinflamamtory agents; antidiabetic agents; autoimmune disease; leukemia | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | PARP1 1569/4885HDAC1 1562/4885MAPK14 1220/4885 |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | PARP1 2042/4885HDAC1 2036/4885MAPK14 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.